Drug Profile
NK 012
Alternative Names: NK012; Polymeric micelle camptothecin analogue - Nippon KayakuLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Nippon Kayaku
- Class Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer; Small cell lung cancer; Triple negative breast cancer
- No development reported Solid tumours
- Discontinued Multiple myeloma
Most Recent Events
- 24 Sep 2021 Discontinued - Phase-II for Multiple myeloma in Japan (IV)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (IV, Infusion)